United States Patent 7,153,889: Critical Claim Review and US Patent Landscape

United States Patent 7,153,889 is a late-generation, chemistry-led US patent with a very broad Markush claim set (Claim 1) anchored to a core scaffold and extensive substituent freedom, then narrowed in dependent claims to particular linker modalities, heteroaryl/heterocycle selections, saturated ring types, and example compounds. The patent’s protection theory is breadth-first: Claim 1 reads as a large structural “box,” while dependent claims tighten to specific embodiment classes and then to a long list of concrete structures. The legal and competitive risk is that the Markush breadth and generic “modulated by histamine-3 receptors” therapeutic statement invite validity challenges (indefiniteness/overbreadth) and make design-around easier than it appears on first read.

What does US 7,153,889 claim, in business terms?

Claim 1: A large Markush “envelope” around a single scaffold family

Claim 1 covers “a compound of the formula” (formula not rendered in the text you provided) or a pharmaceutically acceptable salt/ester/amide/prodrug, where multiple positions are defined as variable sets:

Key structural freedoms (Claim 1):

Y and Y′: each is independently CH or CF.
X, X′, Z, Z′: each is C (i.e., fixed to carbon at multiple positions).
R1 / R2 asymmetry: one of R1 and R2 is from halogen, cyano, or L2R6; the other is from hydrogen, alkyl, alkoxy, aryl, cycloalkyl, halogen, cyano, thioalkoxy.
R3: from hydrogen, alkyl, alkoxy, halogen, cyano, thioalkoxy.
R3a: from hydrogen, methyl, alkoxy, halogen, cyano.
R3b: from hydrogen, alkyl, alkoxy, halogen, hydroxy, cyano, thioalkoxy.
R4 and R5: independently from alkyl / haloalkyl / hydroxyalkyl / alkoxyalkyl / cycloalkyl / cycloalkylalkyl / (NR_AR_B)alkyl, or together with their attached N forms a non-aromatic C3-C6 ring of formula (STR00037).
R6: from aryl, heteroaryl, heterocycle, cycloalkyl.
R7-R10: each independently from hydrogen, hydroxyalkyl, fluoroalkyl, alkyl, with a specific alternative where either (R7,R8) or (R9,R10) form a substituted C3-C6 ring containing 0-2 heteroatoms from O, N, S.
R11-R14: each independently from hydrogen, hydroxy, hydroxyalkyl, alkyl, fluoro.
Q: from bond, O, S, NR15.
L and L2:
- L is either --[C(R16)(R17)]^n-- or --[C(R16)(R17)]^p O--
- L2 is bond, --C(=O)--, --S--, --[C(R18)(R19)]^q--, --NH--, or --N(alkyl)--
R15: from hydrogen, alkyl, acyl, amido, formyl.
R16/R17: hydrogen, alkyl, alkoxy, fluoro.
R18/R19: hydrogen, hydroxy, alkyl, alkoxy, fluoro.
R_x / R_y: hydrogen, hydroxy, alkyl, alkoxy, alkylamino, dialkylamino, fluoro; with a special rule that one can be a covalent bond when taken together on adjacent carbon atoms to represent a double bond.

Numeric parameters (Claim 1):

m: 1 to 5
n: 1 to 6
p: 2 to 6
q: 1 to 4

Practical implication: Claim 1 spans a large combinatorial set. With so many independently selected substituent groups and multiple optional ring-formation pathways, Claim 1 is structured to catch many SAR-driven follow-ons around a histamine-3 receptor (H3R) active scaffold.

Dependent claims narrow to high-value embodiment classes

Dependent claims do not rewrite the central scaffold; they constrain major “axes” that are most likely to be varied during optimization.

Notable narrowing levers in dependent claims:

Claim 2: R1 = bromo, cyano, or L2R6.
Claims 3-6: lock R1 = L2R6 and specify L2 as --CH(OH)--, --C(=O)--, or bond; then restrict R6 to specific aryl and heteroaryl lists, and further to saturated ring-form groups (e.g., azepanyl, azetidinyl, morpholinyl, piperazinyl, etc.).
Claims 7-12: specify R4/R5 alkyl choices and/or formation of defined non-aromatic rings including morpholine and thiomorpholine.
Claims 13-15: require hydroxyalkyl/fluoroalkyl/alkyl substitution patterns, or reduced substitution density.
Claims 21-24: fix integers (m, n, p, q) to smaller sets.
Claims 25-27: lock to a specific minimal parameter state (e.g., Y=Y′=CH, X=X′=Z=Z′=C, and R2=R3=R3a=R3b=H) and specify a heteroaryl group such as 2H-pyridazin-3-one-2-yl.
Claim 26-27: add a specific linker geometry (e.g., n = 2, L is --[C(R16)(R17)]^n-- and R16/R17 are H) and define a substituted methylpyrrolidinyl ring placement pattern.
Claim 28: provides a long list of specific compounds. This is a critical “fallback” evidentiary anchor for written description and enablement, and a practical basis for infringement mapping if any competitor product matches any single enumerated structure.
Claims 29: two specific embodiments are isolated from the broader lists.
Claim 30: composition claim (compound of Claim 1 + pharmaceutically acceptable carrier).
Claim 31: method claim for conditions modulated by H3 receptors including Alzheimer’s disease, ADHD, schizophrenia.

How does the claim strategy shape enforceability and design-around risk?

1) Breadth-first Claim 1 is a litigation posture, not a target list

The Claim 1 Markush set spans:

multiple fluorination and halogenation options (CH/CF at Y/Y′; halogen/cyano at R1/R2/R3/R3a/R3b),
wide aryl/heteroaryl/heterocycle selection (R6),
ring-form transformations for R4/R5 with a non-aromatic nitrogen-containing cycle,
and multiple linker identity classes (L, L2).

That breadth increases the probability that an active compound from a competitor still falls inside the structural envelope. It also increases the probability that an accused compound can be argued as “accidentally included” without clear inventive contribution per subset, which becomes relevant for validity.

Business reading: Claim 1 is likely meant to deter or license a whole class of analogs, while dependent claims and Claim 28 provide specific hooks for enforcement and negotiating leverage.

2) The method claim depends on the chemistry claim being upheld

Claim 31 is constrained by:

administering an effective amount of “a compound of claim 1,”
for H3 receptor-modulated conditions including AD, ADHD, schizophrenia.

If Claim 1 narrows, the method claim collapses with it. If a competitor makes a compound that avoids Claim 1 but still modulates H3R, the method claim becomes hard to reach.

Design-around vector: change one high-level variable that is likely to shift outside the Markush boundaries:

Y/Y′ not both CH/CF choices,
R6 not in the permitted set (e.g., a different aromatic class),
L2 not in the allowed linker modalities,
or R4/R5 ring topology not matching the non-aromatic ring options.

3) Claim 28 enumerations reduce factual and claim-construction friction for specific structures

Claim 28 lists dozens of specific compounds (including multiple stereochemically defined pyrrolidine/piperidine analogs and multiple named heterocycle substitutions). This gives two enforcement advantages:

If any competitor falls on one of these exact structures, infringement is claim-element matching rather than interpretation-heavy.
The list can support argument that the patent’s disclosure already contemplated these embodiments, helping survive written description and enablement scrutiny for those members.

Business reading: The enumerated examples act as “anchor points” for both claim construction and litigation leverage.

What are the competitive center-of-gravity structures in Claim 28?

Claim 28 repeatedly features a dominant motif: a naphthalene-based system linked to a substituted pyrrolidine (often stereodefined as 2R or 2S), with a variety of terminal substituents (benzonitrile, pyridine, pyrimidine, pyridazinone, isoxazole, morpholine, thiomorpholine, etc.). Many compounds are variations around:

2-methyl-1-pyrrolidinyl substituent (often 2R or 2S),
linkers using ethyl or methanone/ethoxy variations,
and heteroaromatic attachments that include nitriles and ring systems.

From a landscape perspective, this suggests the core field the patent targets is H3R-active analogs derived from a naphthyl framework with stereochemically substituted nitrogen-containing rings.

Where are the likely validity and claim-scope friction points?

A. Indefiniteness risk from parameterized and multi-layered Markush logic

Claim 1 uses:

multiple independent substituent sets,
multiple integer parameters (m, n, p, q),
ring formation conditions (e.g., R4/R5 taken together with N forms a ring; alternatively R7/R8 or R9/R10 taken together forms a C3-C6 ring with 0-2 heteroatoms),
and a special covalent-bond rule for R_x/R_y.

This can be enforceable, but it raises typical interpretation questions:

How the “double bond represented between adjacent carbon atoms” rule interacts with covalent-bond representations.
How to interpret “at each occurrence” substitutions where multiple occurrences exist but the formula’s exact mapping to positions is not explicit in your text dump.

Business reading: Even when a court finds the claim definite, the interpretive complexity can increase litigation time and cost for both parties.

B. Overbreadth risk if some Markush members are not supported by data or if breadth is disproportionate

Claim 1 allows extremely broad chemical diversity around R6, substituents, and linker identity. In validity disputes, challengers often argue that:

the claimed genus is broader than what the specification enables across the entire space,
and the patent’s experimental support may focus on a smaller subset.

Claim 28 and dependent claims mitigate this by enumerating numerous structures, but breadth remains large.

C. Functional therapy language is broad and generic

Claim 31 uses a generic pharmacological hook: “condition or disorder modulated by histamine-3 receptors” and lists common CNS indications. This is the typical structure for H3R patents, but it can be attacked as:

functional at the method level rather than tied to specific mechanistic or clinical evidence in the claim language.

What does the dependent-claim narrowing tell us about prosecution intent?

The dependent claim pattern is classic:

start broad (Claim 1 genus),
then lock key discriminating chemical decisions that likely distinguish the prior art (R1/R2 patterns; linker types L and L2; ring types for the nitrogen-containing substituent; heteroaryl selection for R6),
then lock parameter subsets (m, n, p, q),
then present a large set of specific examples (Claim 28) that can be aligned to experimental compounds and/or lead candidates.

This suggests the patent’s commercial value was expected to come from a combination of:

broad cover across analog series,
and strong fallback to specific marketed or lead-like structures.

US patent landscape: what matters around this patent family?

With only the claim text provided here and without the full bibliographic record (filing date, priority, assignee, prosecution history, and related continuations), a complete, evidence-backed landscape mapping cannot be produced without risking fabrication. This analysis therefore limits itself to what is deterministically inferable from the claims you supplied.

Landscape implications that are still actionable

1) H3R-only target narrows infringement across indications but not across analog series

Claim 31 is tied to H3R-modulated conditions, but infringement depends on the chemistry claims for the compound. The chemistry envelope is the main competitive battleground.
Competitors that develop alternate H3R ligands should do a structural element audit against Claim 1’s Markush: Y/Y′ (CH/CF), allowed linker modalities, and the R4/R5 ring formation options.

2) The linker and ring topology are the most “design-around” sensitive elements Because Claim 1 enumerates allowed linker types (L and L2) and allowed ring formations (R4/R5 ring classes), those are the easiest levers to change while retaining general pharmacophore similarity.

3) Enumerated compounds in Claim 28 provide a practical “hit list” If any development candidate matches one of the enumerated structures, risk assessment becomes immediate:

check whether the candidate falls exactly within one enumerated structure (stereochemistry included),
then check whether the candidate’s structural differences avoid the Markush elements that the example uses.

Claim-to-innovation mapping: where competitors are likely to cluster

Based on the claim language, competitors seeking H3R activity with similar scaffold logic would be expected to vary in these axes:

Substitution on the aromatic system (R1/R2/R3/R3a/R3b options include halogens and cyano),
heteroaryl identity (R6) (a long list is allowed),
nitrogen-bearing ring selection (R4/R5 ring) (azetidinyl, azepanyl, morpholine-like, piperazine-like, etc. are allowed),
stereochemistry on the chiral center within the N-ring sidechain (multiple 2R/2S examples appear in Claim 28),
linker class (L2 and Q/O/S/NR15) (modulated by choices that can preserve potency while altering legal coverage).

Business reading: The patent’s breadth suggests many plausible analogs still risk falling within the genus. The clearest design-around opportunity is to change a feature whose allowed set is explicitly constrained, not just “likely.”

Key Takeaways

Claim 1 is a broad Markush genus covering a large combinatorial space around an H3R-active scaffold, with fixed carbon positioning (X/X′/Z/Z′ = C) and limited flexibility at Y/Y′ (CH/CF).
Dependent claims narrow the legal envelope by locking linker modalities (L and L2), ring topologies (R4/R5 non-aromatic N-containing rings), and heteroaryl/heterocycle choices (R6).
Claim 28 is the enforcement spine: it enumerates many specific naphthalene-linked, stereodefined pyrrolidine/piperidine analogs and heteroaryl/nitrile variants. Any candidate matching those exact structures faces direct mapping risk.
Method coverage (Claim 31) is conditional on the chemistry claim. If a competitor avoids Claim 1, the method claim becomes largely irrelevant even if it still modulates H3R.
Most design-around-sensitive elements are likely the linker set (L/L2/Q) and the nitrogen-ring topology and substituent pattern (R4/R5, R7-R10) because those are explicitly enumerated.

FAQs

1) What claim is the primary risk driver?
Claim 1, because it is the broadest structural Markush genus and it underpins both composition (Claim 30) and method (Claim 31) claims.

2) Which claim provides the most concrete enforcement leverage?
Claim 28, because it enumerates dozens of specific compound structures (including stereochemistry) that can be compared directly to candidate molecules.

3) Where is the likely easiest legal design-around?
Changing one of the explicitly enumerated, structurally defining elements in Claim 1, especially the allowed linker classes (L and L2) and the allowed nitrogen-containing ring topologies derived from R4/R5.

4) Does Claim 31 add independent coverage if Claim 1 is avoided?
No. Claim 31 is written as a method of treating H3R-modulated disorders using “a compound of claim 1,” so avoiding Claim 1 avoids the method claim.

5) What do dependent claim parameter locks (m, n, p, q) do strategically?
They create narrower sub-genuses that can serve as fallback coverage if Claim 1 is construed narrowly or attacked, and they help tie the claim set to specific disclosed embodiments.

References (APA)

[1] United States Patent 7,153,889. (Provided claim text).

Title:	Bicyclic-substituted amines as histamine-3 receptor ligands
Abstract:	Compounds of formula (I) ##STR00001## are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
Inventor(s):	Altenbach; Robert J. (Chicago, IL), Black; Lawrence A. (Libertyville, IL), Chang; Sou-Jen (Prairie View, IL), Cowart; Marlon D. (Round Lake Beach, IL), Faghih; Ramin (Lake Forest, IL), Gfesser; Gregory A. (Waukegan, IL), Ku; Yi-Yin (Buffalo Grove, IL), Liu; Huaqing (Buffalo Grove, IL), Lukin; Kirill A. (Mundelein, IL), Nersesian; Diana L. (Gurnee, IL), Pu; Yu-ming (Gurnee, IL), Sharma; Padam N. (Gurnee, IL), Bennani; Youssef L. (Shaker Heights, OH), Curtis; Michael P. (Kenosha, WI)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	10/689,735
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 7,153,889: Critical Claim Review and US Patent Landscape United States Patent 7,153,889 is a late-generation, chemistry-led US patent with a very broad Markush claim set (Claim 1) anchored to a core scaffold and extensive substituent freedom, then narrowed in dependent claims to particular linker modalities, heteroaryl/heterocycle selections, saturated ring types, and example compounds. The patent’s protection theory is breadth-first: Claim 1 reads as a large structural “box,” while dependent claims tighten to specific embodiment classes and then to a long list of concrete structures. The legal and competitive risk is that the Markush breadth and generic “modulated by histamine-3 receptors” therapeutic statement invite validity challenges (indefiniteness/overbreadth) and make design-around easier than it appears on first read. What does US 7,153,889 claim, in business terms? Claim 1: A large Markush “envelope” around a single scaffold family Claim 1 covers “a compound of the formula” (formula not rendered in the text you provided) or a pharmaceutically acceptable salt/ester/amide/prodrug, where multiple positions are defined as variable sets: Key structural freedoms (Claim 1): Y and Y′: each is independently CH or CF. X, X′, Z, Z′: each is C (i.e., fixed to carbon at multiple positions). R1 / R2 asymmetry: one of R1 and R2 is from halogen, cyano, or L2R6; the other is from hydrogen, alkyl, alkoxy, aryl, cycloalkyl, halogen, cyano, thioalkoxy. R3: from hydrogen, alkyl, alkoxy, halogen, cyano, thioalkoxy. R3a: from hydrogen, methyl, alkoxy, halogen, cyano. R3b: from hydrogen, alkyl, alkoxy, halogen, hydroxy, cyano, thioalkoxy. R4 and R5: independently from alkyl / haloalkyl / hydroxyalkyl / alkoxyalkyl / cycloalkyl / cycloalkylalkyl / (NR_AR_B)alkyl, or together with their attached N forms a non-aromatic C3-C6 ring of formula (STR00037). R6: from aryl, heteroaryl, heterocycle, cycloalkyl. R7-R10: each independently from hydrogen, hydroxyalkyl, fluoroalkyl, alkyl, with a specific alternative where either (R7,R8) or (R9,R10) form a substituted C3-C6 ring containing 0-2 heteroatoms from O, N, S. R11-R14: each independently from hydrogen, hydroxy, hydroxyalkyl, alkyl, fluoro. Q: from bond, O, S, NR15. L and L2: L is either --[C(R16)(R17)]^n-- or --[C(R16)(R17)]^p O-- L2 is bond, --C(=O)--, --S--, --[C(R18)(R19)]^q--, --NH--, or --N(alkyl)-- R15: from hydrogen, alkyl, acyl, amido, formyl. R16/R17: hydrogen, alkyl, alkoxy, fluoro. R18/R19: hydrogen, hydroxy, alkyl, alkoxy, fluoro. R_x / R_y: hydrogen, hydroxy, alkyl, alkoxy, alkylamino, dialkylamino, fluoro; with a special rule that one can be a covalent bond when taken together on adjacent carbon atoms to represent a double bond. Numeric parameters (Claim 1): m: 1 to 5 n: 1 to 6 p: 2 to 6 q: 1 to 4 Practical implication: Claim 1 spans a large combinatorial set. With so many independently selected substituent groups and multiple optional ring-formation pathways, Claim 1 is structured to catch many SAR-driven follow-ons around a histamine-3 receptor (H3R) active scaffold. Dependent claims narrow to high-value embodiment classes Dependent claims do not rewrite the central scaffold; they constrain major “axes” that are most likely to be varied during optimization. Notable narrowing levers in dependent claims: Claim 2: R1 = bromo, cyano, or L2R6. Claims 3-6: lock R1 = L2R6 and specify L2 as --CH(OH)--, --C(=O)--, or bond; then restrict R6 to specific aryl and heteroaryl lists, and further to saturated ring-form groups (e.g., azepanyl, azetidinyl, morpholinyl, piperazinyl, etc.). Claims 7-12: specify R4/R5 alkyl choices and/or formation of defined non-aromatic rings including morpholine and thiomorpholine. Claims 13-15: require hydroxyalkyl/fluoroalkyl/alkyl substitution patterns, or reduced substitution density. Claims 21-24: fix integers (m, n, p, q) to smaller sets. Claims 25-27: lock to a specific minimal parameter state (e.g., Y=Y′=CH, X=X′=Z=Z′=C, and R2=R3=R3a=R3b=H) and specify a heteroaryl group such as 2H-pyridazin-3-one-2-yl. Claim 26-27: add a specific linker geometry (e.g., n = 2, L is --[C(R16)(R17)]^n-- and R16/R17 are H) and define a substituted methylpyrrolidinyl ring placement pattern. Claim 28: provides a long list of specific compounds. This is a critical “fallback” evidentiary anchor for written description and enablement, and a practical basis for infringement mapping if any competitor product matches any single enumerated structure. Claims 29: two specific embodiments are isolated from the broader lists. Claim 30: composition claim (compound of Claim 1 + pharmaceutically acceptable carrier). Claim 31: method claim for conditions modulated by H3 receptors including Alzheimer’s disease, ADHD, schizophrenia. How does the claim strategy shape enforceability and design-around risk? 1) Breadth-first Claim 1 is a litigation posture, not a target list The Claim 1 Markush set spans: multiple fluorination and halogenation options (CH/CF at Y/Y′; halogen/cyano at R1/R2/R3/R3a/R3b), wide aryl/heteroaryl/heterocycle selection (R6), ring-form transformations for R4/R5 with a non-aromatic nitrogen-containing cycle, and multiple linker identity classes (L, L2). That breadth increases the probability that an active compound from a competitor still falls inside the structural envelope. It also increases the probability that an accused compound can be argued as “accidentally included” without clear inventive contribution per subset, which becomes relevant for validity. Business reading: Claim 1 is likely meant to deter or license a whole class of analogs, while dependent claims and Claim 28 provide specific hooks for enforcement and negotiating leverage. 2) The method claim depends on the chemistry claim being upheld Claim 31 is constrained by: administering an effective amount of “a compound of claim 1,” for H3 receptor-modulated conditions including AD, ADHD, schizophrenia. If Claim 1 narrows, the method claim collapses with it. If a competitor makes a compound that avoids Claim 1 but still modulates H3R, the method claim becomes hard to reach. Design-around vector: change one high-level variable that is likely to shift outside the Markush boundaries: Y/Y′ not both CH/CF choices, R6 not in the permitted set (e.g., a different aromatic class), L2 not in the allowed linker modalities, or R4/R5 ring topology not matching the non-aromatic ring options. 3) Claim 28 enumerations reduce factual and claim-construction friction for specific structures Claim 28 lists dozens of specific compounds (including multiple stereochemically defined pyrrolidine/piperidine analogs and multiple named heterocycle substitutions). This gives two enforcement advantages: If any competitor falls on one of these exact structures, infringement is claim-element matching rather than interpretation-heavy. The list can support argument that the patent’s disclosure already contemplated these embodiments, helping survive written description and enablement scrutiny for those members. Business reading: The enumerated examples act as “anchor points” for both claim construction and litigation leverage. What are the competitive center-of-gravity structures in Claim 28? Claim 28 repeatedly features a dominant motif: a naphthalene-based system linked to a substituted pyrrolidine (often stereodefined as 2R or 2S), with a variety of terminal substituents (benzonitrile, pyridine, pyrimidine, pyridazinone, isoxazole, morpholine, thiomorpholine, etc.). Many compounds are variations around: 2-methyl-1-pyrrolidinyl substituent (often 2R or 2S), linkers using ethyl or methanone/ethoxy variations, and heteroaromatic attachments that include nitriles and ring systems. From a landscape perspective, this suggests the core field the patent targets is H3R-active analogs derived from a naphthyl framework with stereochemically substituted nitrogen-containing rings. Where are the likely validity and claim-scope friction points? A. Indefiniteness risk from parameterized and multi-layered Markush logic Claim 1 uses: multiple independent substituent sets, multiple integer parameters (m, n, p, q), ring formation conditions (e.g., R4/R5 taken together with N forms a ring; alternatively R7/R8 or R9/R10 taken together forms a C3-C6 ring with 0-2 heteroatoms), and a special covalent-bond rule for R_x/R_y. This can be enforceable, but it raises typical interpretation questions: How the “double bond represented between adjacent carbon atoms” rule interacts with covalent-bond representations. How to interpret “at each occurrence” substitutions where multiple occurrences exist but the formula’s exact mapping to positions is not explicit in your text dump. Business reading: Even when a court finds the claim definite, the interpretive complexity can increase litigation time and cost for both parties. B. Overbreadth risk if some Markush members are not supported by data or if breadth is disproportionate Claim 1 allows extremely broad chemical diversity around R6, substituents, and linker identity. In validity disputes, challengers often argue that: the claimed genus is broader than what the specification enables across the entire space, and the patent’s experimental support may focus on a smaller subset. Claim 28 and dependent claims mitigate this by enumerating numerous structures, but breadth remains large. C. Functional therapy language is broad and generic Claim 31 uses a generic pharmacological hook: “condition or disorder modulated by histamine-3 receptors” and lists common CNS indications. This is the typical structure for H3R patents, but it can be attacked as: functional at the method level rather than tied to specific mechanistic or clinical evidence in the claim language. What does the dependent-claim narrowing tell us about prosecution intent? The dependent claim pattern is classic: start broad (Claim 1 genus), then lock key discriminating chemical decisions that likely distinguish the prior art (R1/R2 patterns; linker types L and L2; ring types for the nitrogen-containing substituent; heteroaryl selection for R6), then lock parameter subsets (m, n, p, q), then present a large set of specific examples (Claim 28) that can be aligned to experimental compounds and/or lead candidates. This suggests the patent’s commercial value was expected to come from a combination of: broad cover across analog series, and strong fallback to specific marketed or lead-like structures. US patent landscape: what matters around this patent family? With only the claim text provided here and without the full bibliographic record (filing date, priority, assignee, prosecution history, and related continuations), a complete, evidence-backed landscape mapping cannot be produced without risking fabrication. This analysis therefore limits itself to what is deterministically inferable from the claims you supplied. Landscape implications that are still actionable 1) H3R-only target narrows infringement across indications but not across analog series Claim 31 is tied to H3R-modulated conditions, but infringement depends on the chemistry claims for the compound. The chemistry envelope is the main competitive battleground. Competitors that develop alternate H3R ligands should do a structural element audit against Claim 1’s Markush: Y/Y′ (CH/CF), allowed linker modalities, and the R4/R5 ring formation options. 2) The linker and ring topology are the most “design-around” sensitive elements Because Claim 1 enumerates allowed linker types (L and L2) and allowed ring formations (R4/R5 ring classes), those are the easiest levers to change while retaining general pharmacophore similarity. 3) Enumerated compounds in Claim 28 provide a practical “hit list” If any development candidate matches one of the enumerated structures, risk assessment becomes immediate: check whether the candidate falls exactly within one enumerated structure (stereochemistry included), then check whether the candidate’s structural differences avoid the Markush elements that the example uses. Claim-to-innovation mapping: where competitors are likely to cluster Based on the claim language, competitors seeking H3R activity with similar scaffold logic would be expected to vary in these axes: Substitution on the aromatic system (R1/R2/R3/R3a/R3b options include halogens and cyano), heteroaryl identity (R6) (a long list is allowed), nitrogen-bearing ring selection (R4/R5 ring) (azetidinyl, azepanyl, morpholine-like, piperazine-like, etc. are allowed), stereochemistry on the chiral center within the N-ring sidechain (multiple 2R/2S examples appear in Claim 28), linker class (L2 and Q/O/S/NR15) (modulated by choices that can preserve potency while altering legal coverage). Business reading: The patent’s breadth suggests many plausible analogs still risk falling within the genus. The clearest design-around opportunity is to change a feature whose allowed set is explicitly constrained, not just “likely.” Key Takeaways Claim 1 is a broad Markush genus covering a large combinatorial space around an H3R-active scaffold, with fixed carbon positioning (X/X′/Z/Z′ = C) and limited flexibility at Y/Y′ (CH/CF). Dependent claims narrow the legal envelope by locking linker modalities (L and L2), ring topologies (R4/R5 non-aromatic N-containing rings), and heteroaryl/heterocycle choices (R6). Claim 28 is the enforcement spine: it enumerates many specific naphthalene-linked, stereodefined pyrrolidine/piperidine analogs and heteroaryl/nitrile variants. Any candidate matching those exact structures faces direct mapping risk. Method coverage (Claim 31) is conditional on the chemistry claim. If a competitor avoids Claim 1, the method claim becomes largely irrelevant even if it still modulates H3R. Most design-around-sensitive elements are likely the linker set (L/L2/Q) and the nitrogen-ring topology and substituent pattern (R4/R5, R7-R10) because those are explicitly enumerated. FAQs 1) What claim is the primary risk driver? Claim 1, because it is the broadest structural Markush genus and it underpins both composition (Claim 30) and method (Claim 31) claims. 2) Which claim provides the most concrete enforcement leverage? Claim 28, because it enumerates dozens of specific compound structures (including stereochemistry) that can be compared directly to candidate molecules. 3) Where is the likely easiest legal design-around? Changing one of the explicitly enumerated, structurally defining elements in Claim 1, especially the allowed linker classes (L and L2) and the allowed nitrogen-containing ring topologies derived from R4/R5. 4) Does Claim 31 add independent coverage if Claim 1 is avoided? No. Claim 31 is written as a method of treating H3R-modulated disorders using “a compound of claim 1,” so avoiding Claim 1 avoids the method claim. 5) What do dependent claim parameter locks (m, n, p, q) do strategically? They create narrower sub-genuses that can serve as fallback coverage if Claim 1 is construed narrowly or attacked, and they help tie the claim set to specific disclosed embodiments. References (APA) [1] United States Patent 7,153,889. (Provided claim text). More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	7,153,889	2023-10-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,153,889

Summary for Patent: 7,153,889